Biotech RadarJobs updated

COMPANY

Cabaletta Bio

HQ: Philadelphia, PA source · cabalettabio.com ↗ · Mid-Atlantic

Clinical Phase 3

Keywords: immunology neurology cell therapy autoimmune diseases systemic lupus erythematosus myositis Generalized Myasthenia Gravis Lupus Nephritis Idiopathic Inflammatory Myopathy Dermatomyositis Anti-Synthetase Syndrome Immune-Mediated Necrotizing Myopathy Juvenile Dermatomyositis Juvenile Polymyositis Juvenile Idiopathic Inflammatory Myopathy Juvenile Myositis Systemic Sclerosis Scleroderma Interstitial Lung Diseases Relapsing Multiple Sclerosis Progressive Multiple Sclerosis Multiple Sclerosis - Relapsing Remitting Multiple Sclerosis Multiple Sclerosis (Relapsing Remitting) Multiple Sclerosis (MS) - Relapsing-remitting Pemphigus Vulgaris MuSK Myasthenia Gravis CABA-201 MuSK-CAART

Location: Philadelphia, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$250.0MRaised (2 yrs)7Trials (company is sponsor)

Timeline

  1. Trial start Phase 1/Phase 2: RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis source ↗
  2. Raise Follow-on offering: $150M (total, as published), announced May 4, 2026. Source: SEC filing. source ↗
  3. Raise Follow-on offering: $100M (total, as published), announced Jun 11, 2025. Source: SEC filing. source ↗
  4. Trial start Phase 1/Phase 2: RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis source ↗
  5. Trial start Phase 2/Phase 3: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis source ↗
  6. Trial start 1: RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus source ↗
  7. Trial start Phase 2/Phase 3: RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopat source ↗
  8. Trial start Phase 1: Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis source ↗
  9. Trial start 1: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA- source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $250.0M. Last 2 years.

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT06359041RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia GravisPhase 1/Phase 2RecruitingDec 17, 20242029-09 (estimated)
NCT06121297RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus1RecruitingFeb 16, 20242029-12 (estimated)
NCT06154252RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyPhase 2/Phase 3RecruitingDec 20, 20232028-07 (estimated)
NCT06328777RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic SclerosisPhase 2/Phase 3RecruitingJul 2, 20242029-07 (estimated)
NCT07006805RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple SclerosisPhase 1/Phase 2Withdrawn2026-062028-09 (estimated)
NCT04422912A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)1RecruitingSep 29, 20202029-01 (estimated)
NCT05451212Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia GravisPhase 1CompletedNov 23, 2022Jul 24, 2025 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback